Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSengupta, Arghya-
dc.description.abstractA contemporary debate in India’s legal and policy circles has centred around the desirability of liberalizing the parallel imports regime in the country. The primary impetus for such a move has been the amendment to Section 107A(b) to the Patents Act in 2005 which allows easier import of products into India which are already under patent protection. This article, focusing specifically on the pharmaceutical sector argues against the all-pervasiveness of such a move in the Indian context. To set the foundation for this argument, the article examines the leading judicial decisions in this regard in the USA and the EU in order to understand the divergent discourses, which exist supporting and opposing freeing of parallel imports. On the basis of these decisions and their applicability to the Indian context, this article proposes a nuanced policy recommendation harmonizing the financial interests of intellectual property owners with those of securing easier availability of key products.en_US
dc.sourceJIPR Vol.12(4) [July 2007]en_US
dc.subjectExhaustion of rightsen_US
dc.subjectParallel importsen_US
dc.titleParallel Imports in the Pharmaceutical Sector: Must India be More Liberal?en_US
Appears in Collections:JIPR Vol.12(4) [July 2007]

Files in This Item:
File Description SizeFormat 
JIPR 12(4) (2007) 400-409.pdf77.54 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.